A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses

NCT05218434 | Completed Phase 1 Results

• 1 other identifier: AX-158-101
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase I Healthy volunteer study with the primary objective to evaluate the safety and pharmacokinetics profile of AX-158. The first part will evaluate single ascending dose administrations. A substudy will be performed as well to evaluate possible impact of food on drug exposure if administered under fasted or fed state. The second part will evaluate multiple ascending dose over 10 days of dosing in fed or fast state depending on the results of the substudy food effect on AX-158.

Conditions

Autoimmune Diseases

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Treatment-Emergent Adverse Events

  The number of participants with recorded treatment emergent adverse events following single and multiple doses of AX-158.

  Up to 10 days of treatment

Secondary Outcomes (3)

• Maximal Plasma Concentration (Cmax)

  Up to 13 days following dose administration

• Total Plasma Drug Exposure (AUC0-t)

  Up to 13 days following dose administration

• Terminal Half Life (t1/2)

  Up to 13 days following dose administration

Study Arms (12)

Part A - 5mg AX-158

EXPERIMENTAL

AX-158 oral Single (Single Ascending Dose)

Drug: AX-158

Part A - 10mg AX-158

EXPERIMENTAL

AX-158 oral Single (Single Ascending Dose)

Drug: AX-158

Part A - 15mg AX-158 or Placebo

EXPERIMENTAL

AX-158 oral Single (Single Ascending Dose)

Drug: AX-158

Part A - 25mg AX-158

EXPERIMENTAL

AX-158 oral Single (Single Ascending Dose)

Drug: AX-158

Part A -50mg AX-158

EXPERIMENTAL

AX-158 oral Single (Single Ascending Dose)

Drug: AX-158

Part B - 15mg AX-158 Fed state

EXPERIMENTAL

AX-158 oral single dose with food

Drug: AX-158

Part B - 15mg AX-158 Fasted

EXPERIMENTAL

AX-158 oral single dose without food

Drug: AX-158

Part C - 5mg AX-158

EXPERIMENTAL

AX-158 oral daily dose for 10 days (Multiple Ascending Dose)

Drug: AX-158

Part C - 10mg AX-158

EXPERIMENTAL

AX-158 oral daily dose for 10 days (Multiple Ascending Dose)

Drug: AX-158

Part C - 15mg AX-158

EXPERIMENTAL

AX-158 oral daily dose for 10 days (Multiple Ascending Dose)

Drug: AX-158

Part A - Placebo

EXPERIMENTAL

Placebo oral Single (Single Ascending Dose)

Drug: AX-158

Part C - Placebo

EXPERIMENTAL

Placebo oral daily dose for 10 days (Multiple Ascending Dose)

Drug: AX-158

Interventions

AX-158 DRUG

Oral administrations of AX-158

Also known as: Placebo

Part A - 10mg AX-158; Part A - 15mg AX-158 or Placebo; Part A - 25mg AX-158; Part A - 5mg AX-158; Part A - Placebo; Part A -50mg AX-158; Part B - 15mg AX-158 Fasted; Part B - 15mg AX-158 Fed state; Part C - 10mg AX-158; Part C - 15mg AX-158; Part C - 5mg AX-158; Part C - Placebo

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy Male participant, between 18 and 50 years of age, inclusive.
• Male participant (and partner of childbearing potential) willing to use a highly effective method of contraception in addition to a condom, if applicable (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the participant) from first dose until 4 months after last dose of Investigational Medicinal Product (IMP).
• Participant with a body mass index (BMI) of 18-30kg/m2. BMI = body weight (kg) / \[height (m)\]2.
• Total serum bilirubin, alkaline phosphatase (ALP), aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 1.5 x upper limit of normal (ULN). If total bilirubin is above the upper limit of normal and is then fractionated, direct bilirubin must be within normal limits.
• Total serum Testosterone levels 2 x above the lower limit of the normal range within 28 days before the first dose administration of the IMP.
• Participant with a negative urinary drugs of abuse (DOA) screen (including alcohol) test results, determined within 28 days before the first dose administration of the IMP (N.B.: A positive test result may be repeated at the Investigator's discretion).
• Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg)) and hepatitis C virus antibody (HCV Ab) test results at Screening.
• No clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 28 days before first dose of IMP including a QRS interval \> 120ms, PR interval \> 220ms and QTcF \> 450ms.
• No clinically significant abnormalities in vital signs (e.g., blood pressure/pulse rate, respiration rate and oral temperature) determined within 28 days before first dose of IMP.
• Participant must be available to complete the study (including all follow-up visits).
• Participant must satisfy an Investigator about his fitness to participate in the study.
• Participant must provide written informed consent to participate in the study.
• Participants with a negative COVID-19 PCR test on admission.

You may not qualify if:

• A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.
• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 28 days or 5 half-lives (whichever is longer) prior to the first dose of IMP. Occasional use of paracetamol will be allowed.
• Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction.
• Clinically significant history of previous allergy / sensitivity to AX-158 or any of the excipients contained within the IMP.
• Participant with history of autoimmune disease, cardiac disease, kidney disease or any food intolerance.
• Participants with clinically significant abnormal test results for serum biochemistry, haematology and/or urine analyses within 28 days before the first dose administration of the IMP
• A clinically significant history of drug or alcohol abuse (defined as the consumption of more than 14 units \[for male and female participants\] of alcohol a week) within the past two years.
• Inability to communicate well with the Investigators (i.e., language problem, poor mental development, or impaired cerebral function).
• Participation in a New Chemical Entity (NCE) clinical study within the previous 3 months or five half-lives, whichever is longer, or a marketed drug clinical study within the 30 days or five half-lives, whichever is longer, before the first dose of IMP. (Washout period between studies is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).
• Donation of 450 milliliters or more blood within the 3 months before the first dose of IMP.
• Vegans, vegetarians, or other dietary restrictions (e.g., restrictions for medical, religious, or cultural reasons, etc), which would prevent participants from consuming a high-fat breakfast or standardised meal.
• Users of nicotine products i.e., current smokers or ex-smokers who have smoked within the 6 months prior to screening or users of cigarette replacements (i.e., e-cigarettes, nicotine patches or gums).
• Participants who have received a COVID-19 vaccine injection within 28 days prior to the first dose of IMP.

Sponsors & Collaborators

• Artax Biopharma Inc: lead
• Simbec-Orion Group: collaborator

Study Sites (1)

Simbec-Orion

Merthyr Tydfil, United Kingdom

Location

Related Publications (9)

• Borroto A, Reyes-Garau D, Jimenez MA, Carrasco E, Moreno B, Martinez-Pasamar S, Cortes JR, Perona A, Abia D, Blanco S, Fuentes M, Arellano I, Lobo J, Heidarieh H, Rueda J, Esteve P, Cibrian D, Martinez-Riano A, Mendoza P, Prieto C, Calleja E, Oeste CL, Orfao A, Fresno M, Sanchez-Madrid F, Alcami A, Bovolenta P, Martin P, Villoslada P, Morreale A, Messeguer A, Alarcon B. First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Sci Transl Med. 2016 Dec 21;8(370):370ra184. doi: 10.1126/scitranslmed.aaf2140.

  PMID: 28003549 BACKGROUND

• Roy E, Togbe D, Holdorf AD, Trubetskoy D, Nabti S, Kublbeck G, Klevenz A, Kopp-Schneider A, Leithauser F, Moller P, Bladt F, Hammerling G, Arnold B, Pawson T, Tafuri A. Nck adaptors are positive regulators of the size and sensitivity of the T-cell repertoire. Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15529-34. doi: 10.1073/pnas.1009743107. Epub 2010 Aug 13.

  PMID: 20709959 BACKGROUND

• Roy E, Togbe D, Holdorf A, Trubetskoy D, Nabti S, Kublbeck G, Schmitt S, Kopp-Schneider A, Leithauser F, Moller P, Bladt F, Hammerling GJ, Arnold B, Pawson T, Tafuri A. Fine tuning of the threshold of T cell selection by the Nck adapters. J Immunol. 2010 Dec 15;185(12):7518-26. doi: 10.4049/jimmunol.1000008. Epub 2010 Nov 15.

  PMID: 21078909 BACKGROUND

• Gil D, Schamel WW, Montoya M, Sanchez-Madrid F, Alarcon B. Recruitment of Nck by CD3 epsilon reveals a ligand-induced conformational change essential for T cell receptor signaling and synapse formation. Cell. 2002 Jun 28;109(7):901-12. doi: 10.1016/s0092-8674(02)00799-7.

  PMID: 12110186 BACKGROUND

• Juraske C, Wipa P, Morath A, Hidalgo JV, Hartl FA, Raute K, Oberg HH, Wesch D, Fisch P, Minguet S, Pongcharoen S, Schamel WW. Anti-CD3 Fab Fragments Enhance Tumor Killing by Human gammadelta T Cells Independent of Nck Recruitment to the gammadelta T Cell Antigen Receptor. Front Immunol. 2018 Jul 9;9:1579. doi: 10.3389/fimmu.2018.01579. eCollection 2018.

  PMID: 30038626 BACKGROUND

• Borroto A, Arellano I, Blanco R, Fuentes M, Orfao A, Dopfer EP, Prouza M, Suchanek M, Schamel WW, Alarcon B. Relevance of Nck-CD3 epsilon interaction for T cell activation in vivo. J Immunol. 2014 Mar 1;192(5):2042-53. doi: 10.4049/jimmunol.1203414. Epub 2014 Jan 27.

  PMID: 24470497 BACKGROUND

• Borroto A, Arellano I, Dopfer EP, Prouza M, Suchanek M, Fuentes M, Orfao A, Schamel WW, Alarcon B. Nck recruitment to the TCR required for ZAP70 activation during thymic development. J Immunol. 2013 Feb 1;190(3):1103-12. doi: 10.4049/jimmunol.1202055. Epub 2012 Dec 24.

  PMID: 23267019 BACKGROUND

• Lettau M, Pieper J, Gerneth A, Lengl-Janssen B, Voss M, Linkermann A, Schmidt H, Gelhaus C, Leippe M, Kabelitz D, Janssen O. The adapter protein Nck: role of individual SH3 and SH2 binding modules for protein interactions in T lymphocytes. Protein Sci. 2010 Apr;19(4):658-69. doi: 10.1002/pro.334.

  PMID: 20082308 BACKGROUND

• Yiemwattana I, Ngoenkam J, Paensuwan P, Kriangkrai R, Chuenjitkuntaworn B, Pongcharoen S. Essential role of the adaptor protein Nck1 in Jurkat T cell activation and function. Clin Exp Immunol. 2012 Jan;167(1):99-107. doi: 10.1111/j.1365-2249.2011.04494.x.

  PMID: 22132889 BACKGROUND

MeSH Terms

Conditions

Autoimmune Diseases

Condition Hierarchy (Ancestors)

Immune System Diseases

Results Point of Contact

• Title: Dr Annelize Koch
• Organization: Simbec Orion

gabrielle.brill@simbecorion.com

01443694313

Study Officials

• Dr Annelize Koch

  Simbec-Orion Merthyr Tydfil CF48 4DR, United Kingdom

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 2, 2021
• First Posted: February 1, 2022
• Study Start: November 17, 2021
• Primary Completion: November 16, 2022
• Study Completion: December 3, 2022
• Last Updated: August 23, 2024
• Results First Posted: August 23, 2024

Record last verified: 2024-08

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)